The effectiveness of methylethylpiridinol in the treatment of nephropathy in patients with diabetes mellitus type I
Abstract
THE AIM: To estimate the effectiveness of nephroprotective properties of methylethylpiridinol in patients with type I diabetes mellitus (DM). PATIENTS AND METHODS. We examined 34 patients with type I DM with signs of diabetic nephropathy. All patients were treated by methylethylpiridinol. Before and after the course of therapy we determined albuminuria levels, vWF activity, adhesion and aggregation of platelets. RESULTS. Prior to treatment in patients with diabetes was diagnosed microalbuminuria MA (91.2%), increase of vWF activity, platelet adhesion and aggregation. Glomerular filtration rate decrease revealed in 60.6% of patients, and hyperfiltration in 9.1% of patients. Revealed decrease of the peak and end-diastolic flow velocity in right segmental renal artery. After treatment was detected the positive dynamics in patients. Decreased adhesion and aggregation of platelets to level of control group. Decreased vWF activity. Increased the number of patients with normal glomerular filtration rate. An improvement of blood flow in segmental renal artery. CONCLUSIONS. In patients with type I diabetes noticed the platelets functional activity increase and development of endothelial dysfunction. Therapy by methylethylpiridinol normalized these factors which provided inclusion of methylethylpiridinol in complex diabetic nephropathy treatment.
About the Authors
E. S. Krutikov
S.I Georgievsky Medical academy V.I.Vernadsky Crimean Federal University
Russian Federation
Russian Federation
V. A. Zhitova
Medical center Avicenna
Russian Federation
Russian Federation
References
1. van den Oever IAM, Raterman HG, Nurmohamed MT et al. Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus. Mediators of Inflammation 2010;ID 792393. doi:10.1155/2010/792393
2. Смирнов АВ, Добронравов ВА, Кисина АА и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015; 19(1): 67-77
3. Бобкова ИН, Шестакова МВ, Щукина АА. Диабетическая нефропатия - фокус на повреждение подоцитов. Нефрология 2015;19(2):33-44
4. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type
5. diabetes mellitus. J Physiol Pathophysiol 2013; 4(4):46-57. doi:10.5897/JPAP2013.0001
6. Kyrgios I, Maggana I, Giza S et al. Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus. Diabetes & Vascular Disease Research 2014;11(3):208-216
7. Nazratuna N, Mahmooda AA, Kuppusamya UR et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vascular Medicine 2006;11:245-250
8. Ferreiro JL, Gomez-Hospital JA, Dominick J. Angiolillo Platelet abnormalities in diabetes mellitus. Diabetes & Vascular Disease Research 2010;7(4):251-259. doi:10.1177/1479164110383994
9. Hall HM, Banerjee S, McGuire DK. Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diabetes & Vascular Disease Research 2011;8(4):245-253
10. Бондаренко ИЗ, Ширшина ИА. Механизмы тромбообразования, ассоциированные с сахарным диабетом: что определяет прогноз интервенционного вмешательства? Сахарный диабет 2013; (3):58-63. doi:http://dx.doi. org/10.14341/2072-0351-95
Review
For citations:
Krutikov E.S., Zhitova V.A. The effectiveness of methylethylpiridinol in the treatment of nephropathy in patients with diabetes mellitus type I. Nephrology (Saint-Petersburg). 2016;20(5):24-29. (In Russ.)
Views:
733
Email this article 